New hepatitis C drugs that shorten treatment times are largely cost-effective despite their hefty U.S. price tags, according to two new analyses.
Breaking News
U.S. stocks rose for a fourth straight session on Monday, with both the Dow and S&P 500 ending at records as large-cap technology shares gained and offset continued weakness in energy names.
France will tax drugmakers whose costly hepatitis C drugs threaten to throw off course its healthcare budget, the government has said, heaping pressure on pharmaceutical companies like Gilead Sciences to cut their prices.
Subscribe to VCpost newsletter
Most Popular
- Doctors Raise Concerns Over Proposed Capital Gains Tax Changes
- Celebrity Designer Nancy Gonzalez Jailed for Smuggling Crocodile, Python Handbags
- Where's My Child Tax Credit 2024: When to Receive My Money After April 15 Tax Filing Deadline?
- IBM Set to Acquire HashiCorp in Possible Mega-Deal, Stock Skyrockets 24% to $6.1 Billion Valuation
- Stellantis Plans to Lay Off Unspecified Number of Workers at US Factories in Coming Months
- Student Loan Forgiveness Processing for This Group of Borrowers Will Stop Next Week
- New Biden Administration Rule to Grant 4 Million Workers Overtime Pay; Here's What You Need to Know!
- Oracle CEO Reveals Plans to Relocate World Headquarters to Nashville, Citing the City’s Reputation as Well-Established Health Center
